Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

First Trust Innovation Leaders ETF

40.13
+0.52001.31%
Post-market: 40.130.00000.00%19:30 EDT
Volume:50.21K
Turnover:2.02M
Market Cap:359.16M
PE:- -
High:40.35
Open:40.15
Low:39.98
Close:39.61
52wk High:40.99
52wk Low:28.19
Shares:8.95M
Float Shares:8.95M
Volume Ratio:0.63
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Lenovo AI Express with Nvidia Accelerates Path to Hybrid AI Factory in Weeks

THOMSON REUTERS
·
Sep 30

Coreweave Delivers Nvidia Vera Rubin Nvl72 Performance at Production Scale, Starting with Cognition

THOMSON REUTERS
·
Sep 30

HPE Secures $1.2B Deal to Provide Cloud Company Vultr with AMD Helios AI Racks

Dow Jones
·
Sep 30

UPS Stock Forecast: Nearly 7% Dividend Yield Meets a Holiday Recovery Test

TradingKey
·
Sep 30

CScale Raises $145 Million for AI Networking, with Backing from Nvidia and Intel

Reuters
·
Sep 30

What the History of Electric Wires Can Teach Us About the Data Center Backlash

InvestorPlace
·
Sep 30

Breaking: Jensen Huang Set to Take On Role at Tsinghua University

Deep News
·
Sep 30

Silo Pharma Unit QwikAgents Adds Nvidia Nemotron Model Support

Reuters
·
Sep 30

Silo Pharma’s Qwikagents Expands AI Agent Platform with Nvidia Model Support and New Runtime Flexibility

THOMSON REUTERS
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Hewlett Packard Enterprise Secures $1.2 Billion Vultr Order for AMD Helios Systems; Shares Rise Pre-Bell

MT Newswires Live
·
Sep 30

Amazon Price Target Raised to $360.00/Share from $335.00 by Rosenblatt

Dow Jones
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

It's Inflation Day and the Stock Market is on Edge

Dow Jones
·
Sep 30

Hpe Secures Its First Amd Helios Order in $1.2 Billion Deal with Vultr

THOMSON REUTERS
·
Sep 30
More